Figures & data
Moreira FA, Wotjak CT. 2010. Cannabinoids and anxiety. Curr Top Behav Neurosci. 2:429–450. Herman JP, Figueiredo H, Mueller NK, Ulrich-Lai Y, Ostrander MM, Choi DC, Cullinan WE. 2003. Central mechanisms of stress integration: Hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness. Front Neuroendocrinol. 24:151–180. de Kloet RE, Joëls M, Holsboer F. 2005. Stress and the brain: From adaptation to disease. Nat Rev Neurosci. 6:463–475. Pecoraro N, Dallman MF, Warne JP, Ginsberg AB, Laugero KD, la Fleur SE, Houshyar H, Gomez F, Bhargava A, Akana SF. 2006. From Malthus to motive: How the HPA axis engineers the phenotype, yoking needs to wants. Prog Neurobiol. 79:247–340. Di S, Malcher-Lopes R, Halmos KC, Tasker JG. 2003. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: A fast feedback mechanism. J Neurosci. 23:4850–4857. Tasker JG, Di S, Malcher-Lopes R. 2006. Minireview: Rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology. 147:5549–5556. McEwen BS. 1998. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci. 840:33–44. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. 2004. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic–pituitary–adrenal axis. Endocrinology. 145:5431–5438. Steiner MA, Wotjak CT. 2008. Role of the endocannabinoid system in regulation of the hypothalamic–pituitary–adrenocortical axis. Prog Brain Res. 170:397–432. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology. 2009b; 34:2733–2745. Ginsberg AB, Pecoraro NC, Warne JP, Horneman HF, Dallman MF. 2010. Rapid alterations of stress-induced hypothalamic–pituitary–adrenal hormone secretion in the rat: A comparison of glucocorticoids and cannabinoids. Stress. 13:248–257. Patel S, Roelke CT, Rademacher DJ, Hillard CJ. 2005. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signaling. Eur J Neurosci. 21:1057–1069. Patel S, Hillard CJ. 2008. Adaptations in endocannabinoid signaling in response to repeated homotypic stress: A novel mechanism for stress habituation. Eur J Neurosci. 27:2821–2829. Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TTY, Gray JM, Hillard CJ, Gorzalka BB, Viau V. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA. 2010b; 107:9406–9411. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. 2002. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology. 159:379–387. Hill MN, Gorzalka BB. 2004. Enhancement of anxiety-like responsiveness to the cannabinoid receptor agonist HU-210 following chronic stress. Eur J Pharmacol. 499:291–295. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, Gorzalka BB. 2005. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 30:508–515. Hill MN, Gorzalka BB. 2005. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol. 16:333–352. Bambico FR, Gobbi G. 2008. The cannabinoid CB1 receptor and the endocannabinoid anadamide: Possible antidepressant targets. Expert Opin Ther Targets. 12:1347–1366. Gorzalka BB, Hill MN, Hillard CJ. 2008. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosci Biobehav Rev. 32:1152–1160. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci. 2009a; 30:484–493.